Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer.

Viladiu, P.; Bosch, F. Xavier; Castellsagué, Xavier; Muñóz, Núbia; Escribà, Josep M.; Hamšíková, Eva; Hofmannová, Vanda; Guerrero, E; Izquierdo, Ana; Navarro, Carmen; Moreo, Pilar; Izarzugaza, Isabel; Ascunce, Nieves; Gili, M; Muñoz, María Teresa Gómez; Tafur, Luis Alberto; Shah, Keerti V.; Vonka, V.

doi:10.1200/jco.1997.15.2.610

Cited by 37 publications

(26 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although some studies reported a poorer prognosis if no HPV virus was detected, 9 -11 other authors came to different conclusions. [12][13][14][15][16][17] The presence of HPV type 18 has been identified as a predictor of early recurrence and poor survival. [5][6][7][8] A recent study found improved survival in patients with HPV 58 positive tumors.…”

Section: Discussionmentioning

confidence: 99%

“…[5][6][7][8] For other HPV types, the absence of detected HPV DNA sequences was reported to be associated with poor prognosis, 9 -11 whereas others found no relationship between HPV and outcome. [12][13][14][15][16][17] Most of these studies included patients who had received either surgery or a combination of surgery and radiotherapy. Although the standard treatment of locally advanced cervical cancer includes radiotherapy, little is known about the impact of HPV on the response to radiotherapy and on the patients' clinical outcome.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer

Bachtiary

Obermair

Dreier

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

To obtain information on the incidence and the clinical significance of infection with various types of the human papillomavirus (HPV) in cancer of the uterine cervix, we retrospectively examined the HPV status of 106 patients who had received radical radiotherapy for cervical cancer stages IB to IIIB. DNA was extracted from formalin-fixed, paraffinembedded biopsies and PCR was carried out to identify HPV types 16, 18, 31, 35, 33 and 45. To detect additional HPV types, consensus PCR products were cloned and sequenced. A catalyzed signal-amplified colorimetric in situ hybridization was carried out in 84 of 106 specimens as a positive control. Response to therapy, progression-free survival (PFS) and cervical cancer-specific survival (CCSS) were the statistical endpoints. Survival analysis was carried out using univariate and multivariate analysis (Cox regression). Ninety-six patients (90.6%) were HPV-positive and 42/96 (43.7%) were positive for multiple HPV types. Eight patients had persistent disease after radiotherapy. From these 8 patients, 7 were infected with multiple HPV types and only 1 patient had an infection with a single HPV type. After a median follow up period of 50 months, patients with multiple HPV infection had a significantly shorter PFS and CCSS compared to those with single HPV infection (24.8% and 34.9% vs. 64% and 60.8%, Log rank, p < 0.01 and 0.04). In multivariate analysis, the presence of multiple HPV types (RR 1.9), node status (RR 2.3), tumor size (RR 3.2) and histologic type (RR 4.8) were independent prognostic factors of CCSS. Our results demonstrate that the presence of multiple HPV types is associated with poor response and with reduced survival in cervical cancer patients who receive radiotherapy as the primary treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer

Bachtiary

Obermair

Dreier

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…23,[29][30][31] The second point concerns the differential prognostic value of HPV genotypes in invasive cancer. We 16 and others 14,22,28,[32][33][34][35][36][37][38][39][40] reported an unfavourable outcome of tumours associated with HPV18 as compared with those associated with HPV16 or with intermediate-risk HPV types. In this work, based on the analysis of a larger number of cases with a long follow up, the better outcome of tumours associated with intermediate-risk HPV was confirmed, but the respective prognostic value of HPV18 vs. HPV16 showed little differences.…”

Section: Discussionmentioning

confidence: 99%

“…17 All HPV negative cases were reviewed histologically to confirm the diagnosis and to check the representative character of the tissue specimens. The corresponding DNA preparations were further analyzed by AMPLICOR HPV test (Roche Molecular Systems, Inc, Branchburg, NJ) that utilizes amplification of target DNA by PCR followed by nucleic acid hybridization for the detection of 13 high-risk HPV types (16,18,31,33,35,39,45, 51, 52, 56, 58, 59 and 68). 18 Samples that were found positive with GP51/GP61 primers and/or AMPLICOR HPV test but negative for HPV type 16, 18, 33, 45, 6 and 11 were then HPV genotyped by reverse hybridization using the Roche Linear Array genotyping test (Roche Molecular Systems, Inc, Branchburg, NJ) that identifies 37 different anogenital HPV DNA genotypes.…”

Section: Patientsmentioning

confidence: 99%

Different outcome of invasive cervical cancer associated with high‐risk versus intermediate‐risk HPV genotype

Crémoux

Rochefordière

Savignoni

et al. 2008

Intl Journal of Cancer

View full text Add to dashboard Cite

Human papillomavirus (HPV) DNA sequences are associated with the large majority of invasive cervical carcinoma but the role of specific genotype(s) in the outcome of the disease is still debated. To determine the viral epidemiology in the French population of patients and the prognostic value of HPV genotypes in cervical cancer, we performed a retrospective study in 515 patients treated in our Institution from 1985 to 2005. Ninety-six percent of the cases were found associated with HPV DNA whereas 4% remained HPV negative. High-risk HPV 16/18 genotypes were found in 70% of the cases. HPV 18 was more frequently associated with adenocarcinoma (40.6%) than HPV 16 (10.4%) and found in tumours developed in younger women (mean age, 45.8 years) than HPV 16 (48.3 years) or other HPV types (53.6 years). In multivariate analysis, node involvement (p < 0.0001), parametria invasion (p 5 0.009), tumour size (p 5 0.01) and HPV status (p 5 0.02) were associated with disease-free survival (median follow-up 95 months). Disease outcome was better in tumours associated with intermediate risk HPV types (HPV 31,33,35,39, 52, 53, 58, 59, 73) than in tumours with high oncogenic types (HPV 16, 18, 45) (p 5 0.03). Node status and tumour size remained prognostic factor for overall survival. Our data show that HPV genotype is one of the biological factors associated with the outcome of cervical cancer. One third of invasive carcinoma were not associated with HPV 16/18, indicating that the screening for cervical neoplasia should be maintained after prophylactic vaccination against these HPV genotypes. ' 2008 Wiley-Liss, Inc.Key words: cervical cancer; HPV; prognosis Human papillomavirus (HPV) DNA sequences are associated with most of invasive cervical carcinoma worldwide 1 and the role of HPV as a causative agent of cervical neoplasia is well documented. 2 There is a large plurality of HPV types since more than 100 different genotypes have been identified 3 among which more than 40 infect ano-genital mucosa. Histological and virological analyses have shown that 3 groups of genital HPV could be identified according to their oncogenic properties. Low-risk HPVs (HPV6,11,42,43, 44. . .), present in low grade cervical intraepithelial neoplasia (CIN) but rare in invasive cancer, intermediaterisk HPVs (HPV 31,33,35, 51, 52, 58. . .), more prevalent in CIN than in invasive cancer, and high-risk HPVs (HPV16, 18, 45, 56. . .), more frequently found in invasive carcinoma than in CIN. 4 Experimental data have disclosed that high-risk E6 and E7 oncoprotein act in the tumour process by interfering with cell cycle G1-S checkpoint. 5 Virological epidemiology data show that HPV16 and HPV18 are the most prevalent genotypes found in invasive carcinoma worldwide but that there are significant geographic variations in the prevalence of less common genotypes. 6 In the perspective of prophylactic vaccination, it is thus necessary to accurately determine the prevalence of the different HPV types in cervical cancer at country level. Moreover, controversial data...

show abstract

“…También se ha encontrado utilidad de la determinación de RNAm y DNA de HPV en pacientes con cáncer cervicouterino por su asociación con el pronóstico de la enfermedad (44,45,46), y de la determinación de anticuerpos contra HPV en pacientes con cáncer cervicouterino como predictores de sobrevida (47).…”

Section: Investigación Actual Y Futuraunclassified

Cancer Cervicouterino: Epidemiologia, Historia Natural Y Rol Del Virus Papiloma Humano: Perspectivas en Prevencion Y Tratamiento

Serman

2002

Rev. chil. obstet. ginecol.

View full text Add to dashboard Cite

Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer.

Abstract: The presence of antibodies to HPV 16 E7 proteins is of prognostic value in early-stage cervical cancer. Our results provide strong evidence that detection and typing of HPV DNA in cervical cells or tissues is not a prognostic factor for recurrence or survival.

Cited by 37 publications

References 23 publications

Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer

Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer

Different outcome of invasive cervical cancer associated with high‐risk versus intermediate‐risk HPV genotype

Cancer Cervicouterino: Epidemiologia, Historia Natural Y Rol Del Virus Papiloma Humano: Perspectivas en Prevencion Y Tratamiento

Contact Info

Product

Resources

About